ClinicalTrials.gg
CompletedNCT00176462Updated Jun 9, 2014Results posted

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

A Phase 2 interventional study of aminopterin and L-asparaginase in Acute Lymphocytic Leukemia, sponsored by Rutgers, The State University of New Jersey. Completed at 2 sites in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Rutgers, The State University of New Jersey · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
1 Year to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 28 open to participants now, 45 under way, 7 of them phase 3. Cyclophosphamide · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
67th of 179
60 · median 47
Started
2001
with 3 others
Phase 2
104 of 187
15 open now
Registered
45th of 187
by date

Among the 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 67th largest by enrollment of the 179 interventional ones that give a count, is one of 4 that started in 2001, is one of 104 in phase 2, and was the 45th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

28 of the 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 28 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for relapse of their leukemia.

Read the detailed description

Outline of Therapy:

Combinations of chemotherapy drugs will be given orally, intravenously and intrathecally (directly into the cerebrospinal fluid by spinal tap) over a period of roughly two and a half years.

Therapy will be divided into five phases:

Induction (4 weeks): chemotherapy given to produce a clinical remission (defined by normal blood counts, with the absence of leukemia cells in the blood and fewer than 5% leukemia cells in the bone marrow).

Consolidation (11 weeks): chemotherapy given to consolidate the remission. Delayed Intensification (7 weeks) Intensive chemotherapy aimed at killing any resistant leukemia cells will be given only for patients at high risk of relapse.

Intensive Continuation (approximately 1 year): Eight week cycles of chemotherapy, given eight times.

Continuation (final year of therapy): Eight week cycles of largely oral chemotherapy, with one clinic visit for a lumbar puncture every eight weeks.

Irradiation: radiation will be given in the middle of intensive continuation to the head and spine of those patients who have leukemia cells found in the cerebrospinal fluid at the time of diagnosis.

Follow-up: After the conclusion of therapy, there will be periodic office visits, initially monthly, then gradually spaced out to annual visits. The purpose of these visits is to evaluate for late side-effects of therapy.

03

Conditions studied

  • Acute Lymphocytic Leukemia

Keywords

  • Acute Lymphocytic Leukemia
  • Leukemia
04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly Diagnosed ALL, excluding mature B-cell ALL (surface Ig positive)
  • Patients with overt CNS (central nervous system) or testicular disease are eligible
  • according to institutional and FDA guidelines.
  • Adequate organ function is required.
  • seropositive patients will not be excluded from this study.
  • Patients greater than 1 year of age and less than 29.99 years of age are eligible.

Exclusion criteria

Exclusion Criteria

  • Patients with medical, psychological, or psychiatric problems that are likely to compromise their ability to tolerate intensive therapy will be ineligible.
  • All patients with evidence of significant organ dysfunction not thought to be attributable to ALL (patients with congestive heart failure, cardiac \<40%, total >2, serum creatinine >2) will be ineligible. Note: echocardiogram or MUGA are required prior to therapy ONLY for those patients with history or physical findings suggestive of cardiac dysfunction not directly attributable to anemia or ALL. Note: Patients with total bilirubin >2 but direct (conjugated) bilirubin less than the will still be eligible. These patients should be evaluated for deficiency of the enzyme glucuronyl transferase.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Arm 1 Standard Risk

    6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin

    Drug: L-asparaginase · Drug: daunomycin · Drug: dexamethasone · Drug: 6-mercaptopurine · Drug: methotrexate · Drug: vincristine · Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone) · Drug: Leucovorin

  • Experimental
    Arm 2 High Risk

    6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C

    Drug: aminopterin · Drug: L-asparaginase · Drug: cyclophosphamide · Drug: cytarabine · Drug: daunomycin · Drug: dexamethasone · Drug: 6-mercaptopurine · Drug: 6-thioguanine · Drug: vincristine · Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone) · Drug: Leucovorin

Interventions

  • Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • DrugAsparaginaseStudies of AsparaginaseAsparaginase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • DrugDaunorubicinStudies of DaunorubicinDaunorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • DrugMercaptopurineStudies of MercaptopurineMercaptopurine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • DrugThioguanineStudies of ThioguanineThioguanine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

  • DrugTriple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)
06

What researchers measure

Primary outcomes

  1. Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years

    This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission.

    Time frame: 5 years

Secondary outcomes

  1. To Measure 5-methyltetrahydrofolate, Aminopterin and Methotrexate Uptake in Leukemic Blasts Isolated at Diagnosis

    Time frame: 5 years

07

Results

Posted Jun 9, 2014
Limitations and caveats
Antifolate therapy was non-randomly assigned, therefore, we do not have a statistical basis to compare the toxicity observed among patients on the standard risk and high risk treatment arms.

Participant flow

59 patients with ALL were enrolled between March, 2001 and September, 2005 at the Cancer Institute of New Jersey (outpatient clinical research facility) and 1 patient was enrolled at Jersey Shore University Medical Center (a community hospital).

Induction (4 Weeks)
Participant flow — Induction (4 Weeks)
MilestoneArm 1 Standard RiskArm 2 High Risk
Started2139
Completed2034
Not completed15
Withdrew: Withdrawal by subject02
Withdrew: Death12
Withdrew: Lack of efficacy01
Consolidation (12 Weeks)
Participant flow — Consolidation (12 Weeks)
MilestoneArm 1 Standard RiskArm 2 High Risk
Started2034
Completed2029
Not completed05
Withdrew: Patient moved to another state01
Withdrew: Adverse event01
Withdrew: Lack of efficacy02
Withdrew: Not documented01
Delayed Intensification (8 Weeks)
Participant flow — Delayed Intensification (8 Weeks)
MilestoneArm 1 Standard RiskArm 2 High Risk
Started2029
Completed2029
Not completed00
Intensive Continuation (8X8-week Cycles)
Participant flow — Intensive Continuation (8X8-week Cycles)
MilestoneArm 1 Standard RiskArm 2 High Risk
Started2029
Completed1926
Not completed13
Withdrew: Death10
Withdrew: Lack of efficacy03
Continuation -up to 30mos Post Remission
Participant flow — Continuation -up to 30mos Post Remission
MilestoneArm 1 Standard RiskArm 2 High Risk
Started1926
Completed1926
Not completed00

Outcome measures

PrimaryPercentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years

This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission.

Time frame:
5 years
Reported as:
Number · percentage of participants
Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
percentage of participantsArm 2 High Risk
Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years64.9
SecondaryTo Measure 5-methyltetrahydrofolate, Aminopterin and Methotrexate Uptake in Leukemic Blasts Isolated at Diagnosis
Time frame:
5 years

No measurements were reported for this outcome.

Adverse events

Collected over 7 years, 6 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 Standard Risk—20/21 (95.2%)21/21 (100%)
Arm 2 High Risk—36/39 (92.3%)39/39 (100%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventArm 1 Standard RiskArm 2 High Risk
Febrile neutropeniaInfections and infestations16/2117/39
PlateletsBlood and lymphatic system disorders5/215/39
Infection without neutropeniaInfections and infestations3/211/39
Pneumonitis/pulmonary infiltratesRespiratory, thoracic and mediastinal disorders3/212/39
Muscle weakness (not due to neuropathy)Musculoskeletal and connective tissue disorders0/215/39
DyspneaRespiratory, thoracic and mediastinal disorders2/211/39
Infection with unknown ANCInfections and infestations1/213/39
DehydrationGastrointestinal disorders0/213/39
AnorexiaGeneral disorders0/213/39
HemoglobinBlood and lymphatic system disorders1/213/39
Most frequent other events
Showing 10 of 57
Most frequent other events
EventArm 1 Standard RiskArm 2 High Risk
FeverGeneral disorders12/2115/39
VomitingGastrointestinal disorders2/217/39
Headache - Pain-HeadGeneral disorders0/217/39
Allergic reaction/hypersensitivityImmune system disorders3/210/39
Other ToxicityGeneral disorders3/215/39
DehydrationGastrointestinal disorders1/215/39
Infection with unknown ANCInfections and infestations1/214/39
Abdominal pain or crampingGastrointestinal disorders1/214/39
Stomatitis / pharyngitisGastrointestinal disorders1/214/39
HemoglobinBlood and lymphatic system disorders2/210/39

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1 Standard RiskArm 2 High RiskTotal
<=18 years213051
Between 18 and 65 years099
>=65 years000
Age, Continuous
Age, Continuous(years)Arm 1 Standard RiskArm 2 High RiskTotal
Mean3.71 ± 1.7716 ± 9.811.7 ± 9.89
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 Standard RiskArm 2 High RiskTotal
Female111829
Male102131
Region of Enrollment
Region of Enrollment(participants)Arm 1 Standard RiskArm 2 High RiskTotal
United States213960
08

Study locations

2 sites
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07754, United States
  • Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
Feb 2001
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Jun 9, 2014
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00176462
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Feb 2001
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Jun 9, 2014
Last update
Jun 9, 2014

Study contacts

Barton Kamen, MD
principal investigator · Rutgers, The State University of New Jersey

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aminopterin · Cyclophosphamide · Cytarabine · Methotrexate · Thioguanine

Start the discussion